Are statins anti-inflammatory?

Current Controlled Trials in Cardiovascular Medicine

Volumn 1, Issue 3, 2000, Pages 161-165

  Blake, G J ^a   Ridker, P M ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Atherosclerosis; C reactive protein; Inflammation; Statins

Indexed keywords

AMYLOID A PROTEIN; ANTILIPEMIC AGENT; ANTIOXIDANT; ATORVASTATIN; C REACTIVE PROTEIN; CD11B ANTIGEN; CHOLESTEROL; COLESTYRAMINE; FLUINDOSTATIN; FREE RADICAL; GELATINASE B; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; INTERSTITIAL COLLAGENASE; LEUKOTRIENE B4; LIPID; LOW DENSITY LIPOPROTEIN; MATRIX METALLOPROTEINASE; MEVALONIC ACID; MEVINOLIN; MONOCYTE CHEMOTACTIC PROTEIN 1; NITRIC OXIDE SYNTHASE; PHOSPHOLIPID; PLACEBO; PRAVASTATIN; SIMVASTATIN; SUPEROXIDE; THROMBOCYTE ACTIVATING FACTOR; UNINDEXED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE MARKER; DRUG EFFICACY; HUMAN; MONKEY; NONHUMAN; OUTCOMES RESEARCH; PATIENT SELECTION; RAT; REVIEW; RISK ASSESSMENT; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 0034468508     PISSN: 14686708     EISSN: None     Source Type: Journal    
DOI: 10.1186/CVM-1-3-161     Document Type: Review

References (53)

1. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators
2. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group
3. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study
4. B-Mode ultrasound assessment of pravastatin treatment effect on carotid and femoral artery walls and its correlations with coronary arteriographic findings: A report of the Regression Growth Evaluation Statin Study (REGRESS)
5. Disease-free intervals after partial ileal bypass in patients with coronary heart disease and hypercholesterolemia: Report from the Program on the Surgical Control of the Hyperlipidemias (POSCH)
6. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men
7. C-Reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women
8. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men
9. Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men
10. Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: The Atherosclerosis Risk In Communities (ARIC) study
11. Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly
12. Low grade inflammation and coronary heart disease: Prospective study and updated meta-analyses
13. Atherosclerosis -an inflammatory disease
14. HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages
15. Fluvastatin inhibits matrix metalloproteinase-1 expression in human vascular endothelial cells
16. Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys
17. Contrary effects of lightly and strongly oxidized LDL with potent promotion of growth versus apoptosis on arterial smooth muscle cells, macrophages, and fibroblasts
18. The role of tissue factor pathway inhibitor in a revised coagulation cascade
19. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors
20. Hypolipidemic drugs reduce lipoprotein susceptibility to undergo lipid peroxidation: In vitro and ex vivo studies
21. Simvastatin inhibits the oxidation of low-density lipoproteins by activated human monocyte-derived macrophages
22. Interactions of platelets, macrophages, and lipoproteins in hypercholesterolemia: Antiatherogenic effects of HMG-CoA reductase inhibitor therapy
23. Atorvastatin and gemfibrozil metabolites, but not the parent drugs, are potent antioxidants against lipoprotein oxidation
24. Protective effect of fluvastatin sodium (XU-62-320), a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, on oxidative modification of human low-density lipoprotein in vitro
25. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month
26. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase
27. Effects of fluvastatin on leukocyte-endothelial cell adhesion in hypercholesterolemic rats
28. HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia
29. HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis
30. Inhibitory effect of fluvastatin, an HMG-CoA reductase inhibitor, on the expression of adhesion molecules on human monocyte cell line
31. Statins and monocytes
32. Inhibition of proinflammatory cytokine production by pravastatin
33. Simvastatin inhibits the monocyte expression of proinflammatory cytokines in patients with hypercholesterolemia
34. Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction
35. The cellular functions of small GTP-binding proteins
36. Proapoptotic effect of atorvastatin on stimulated rabbit smooth muscle cells
37. Non-lipid-related effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors
38. Vastatins inhibit tissue factor in cultured human macrophages. A novel mechanism of protection against atherothrombosis
39. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells Role of geranylgeranylation and Rho proteins
40. Current and future treatment of hyperlipidemia: The role of statins
41. Pravastatin therapy in hyperlipidemia: Effects on thrombus formation and the systemic hemostatic profile
42. Inhibition of thrombin generation by simvastatin and lack of additive effects of aspirin in patients with marked hypercholesterolemia
43. Effect of pravastatin on outcomes after cardiac transplantation
44. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators
45. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators
46. Effect of statins on C-reactive protein in patients with coronary artery disease
47. Statins and C-reactive protein
48. C-Reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction
49. Are statins anti-inflammatory? Issues in the design and conduct of the pravastatin inflammation C-reactive protein evaluation